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Introduction
Choroidal osteoma was first described by van Dyk 
in 1975 (1). The tumour is located in the peripapillary area 
and papillary-macular band, hardly ever only in the paramacular 
area (2, 3). The colour of the lesions varies from yellow-white 
to orange-red with or without covering pigment. The colour va-
riation is associated with tumour metabolism depending on de-
pigmentation of the retinal pigment epithelium (1). Intensive 
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Abstract: Aim: To analyse symptoms, disease course, comorbidities, complications and treatment in eleven-year follow-up of patients 
with choroidal osteoma.
 Material and methods: Twelve eyes of 3 men and 8 women were analysed.
 Results: Choroidal neovascularization was observed in 5 eyes (41.6%), intraretinal fluid without features of choroidal neovascu-
larization was observed in one case; there was also a single case of epiretinal membrane. Retinal pigment epithelium and Bruch 
membrane dystrophy alongside accumulation of subretinal fluid and intraretinal haemorrhage were observed in all cases of cho-
roidal neovascularization, there was also one case of subretinal haemorrhage. Two patients with choroidal neovascularization 
were treated with anti-VEGF injections. The photodynamic therapy was used in one case. The majority (86%) of cases without 
choroidal neovascularization had visual acuity of 20/25 or better. In patients with choroidal neovascularization, the majority 
(80%) had visual acuity of 20/40 or lower. Anti-VEGF therapy (ranibizumab) improved visual acuity by 3 rows and stabilised 
it for a period of 20 months. Both discussed treatment methods accelerated decalcification, retinal pigment epithelial atrophy 
and subretinal fibrosis, which slowed down tumour growth.
 Conclusions: Anti-VEGF injections are the best option to inhibit tumour progression and should be used in cases with choroidal 
neovascularization.
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Abstrakt: Cel: Analiza objawów, przebiegu choroby, schorzeń współistniejących, powikłań i stosowanego leczenia w obserwacji długoter-
minowej (11 lat) pacjentów z kostniakiem naczyniówki.
 Materiał i metoda: analizą objęto 12 oczu 3 mężczyzn i 8 kobiet.
 Wynik: W 5 oczach (41,6%) stwierdzono neowaskularyzację podsiatkówkową. W jednym przypadku stwierdzono obecność 
płynu śródsiatkówkowego, któremu nie towarzyszyła neowaskularyzacja posiatkówkowa. W jednym przypadku rozpoznano bło-
nę nasiatkówkową. Dystrofię nabłonka barwnikowego i błony Brucha, oraz płyn podsiatkówkowy i krwotoki śródsiatkówkowe 
obserwowano we wszystkich przypadkach ze współistniejącą neowaskularyzacją podsiatkówkową, w jednym z przypadków 
stwierdzono krwotok podsiatkówkowy. Dwoje pacjentów z neowaskularyzacją podsiatkówkową leczono doszklistkowymi iniek-
cjami anty-VEGF. Terapię fotodynamiczną zastosowano w jednym przypadku. Najlepsza skorygowana ostrość wzroku u większo-
ści (86%) pacjentów bez neowaskularyzacji podsiatkówkowej była wyższa lub równa 20/25, natomiast większość pacjentów 
(80%) z neowaskularyzacją podsiatkówkową miało ostrość wzroku niższą lub równą 20/40. Leczenie anty-VEGF (ranibizumab) 
poprawiało ostrość wzroku o 3 rzędy i stabilizowało ją na okres 20 miesięcy. Obie omówione metody leczenia przyspieszały pro-
cesy dekalcyfikacji, zaniku nabłonka barwnikowego siatkówki i włóknienia podsiatkówkowego, co spowalniało wzrost guza.
 Wnioski: Doszklistkowe iniekcje anty-VEGF stanowią najlepszą opcję hamowania progresji guza i powinny być stosowane 
w przypadkach kostniaka naczyniówki współistniejącego z neowaskularyzacją podsiatkówkową.
Słowa kluczowe: kostniak naczyniówki, guz naczyniówki, terapia anty-VEGF.
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orange-red areas indicate the presence of calcifications, the co-
lour is the result of intact, normal retinal pigment epithelium 
covering the tumour; while white-yellow areas indicate decalci-
fied regions (4). Histologically, the tumour is a dense cancellous 
bone with narrow spaces intersected by dilated thin-walled blo-
od vessels referred to as “spider vessels” or “feeder vessels”. 
Those vessels seem to connect choriocapillaries with larger 
choroidal vessels (1, 5, 6).
https://doi.org/10.5114/ko.2018.81095
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The prevalence of choroidal osteoma remains unknown. 
It is considered an extremely rare tumour as bigger clinical 
centres only report several cases. A study of choroidal oste-
oma in patients of the Wills Eye Hospital demonstrated 74 ca-
ses in 61 patients (13 cases of bilateral choroidal osteoma) 
over the analysed period of 26 years (7). The precise aetiology 
is unknown, as well. Diagnosis is based on characteristic clini-
cal and ultrasound features – the lesion appears hyperechoic. 
Additional diagnosis investigations include optical coherence 
tomography (OCT), fluorescein angiography (FA), indocyanine 
green angiography (ICGA) and computed tomography (CT).
The tumour is metabolically active and grows slowly 
with progressive decalcification, which causes complications 
and visual loss. The study by Shields in 61 patients monitored 
for 10 years demonstrated tumour growth occurring in 51% 
of cases, decalcification – in 50% of cases, and visual acuity 
(VA) of 20/200 or less in 56% of cases (7). Another long-term 
(10-year follow-up) study by Aylwerd et al. on 36 patients sho-
wed tumour growth in 41% of cases and VA of 20/200 or less 
in 58% of cases (8). The complications of choroidal osteoma 
include subretinal fluid accumulation, subretinal neovasculariza-
tion, as well as inter- and/or subretinal haemorrhage. Subretinal 
fluid can accumulate as a result of exfoliation and atrophy of the 
retinal pigment epithelium (RPE) or leakage from abnormal blo-
od vessels of the subretinal membrane. RPE has many physio-
logical functions, one of which includes transportation of fluid 
produced by metabolically active retina to choriocapillaries (9). 
Tumour bone metabolism leads to decalcification causing da-
mage and atrophy of the overlying retinal pigment epithelium 
(8). The second mechanism is the development of choroidal 
neovascularization (CNV). CNV is the most common cause 
of vision loss in patients with choroid osteoma; it occurs in 31% 
to 47% of cases over a 10-year follow-up (4, 7).
Currently, long-term watchful waiting is recommended 
in patients with choroidal osteoma. If tumour growth poses 
a risk to the macula, laser coagulation and PDT were attempted 
in numerous studies to inhibit its further progression.
Material and methods
Twelve eyes of eleven patients (3 men and 8 women) 
with choroidal osteoma were enrolled. All patients underwent 
a comprehensive eye examination and ocular ultrasound. Ad-
ditionally, fluorescein angiography and optical coherent tomo-
graphy were performed in seven cases. OCT examinations 
were performed using TOPCON’s 3D OCT 2000 and Optovue 
tomographs, as Grid, Line, EMM5, 3D Reference scans. Swept 
source OCT (SS-OCT Atlantis DRI OCT-1, Topcon, Japan) was 
used in 3 cases to acquire 3D Macula 6.0 x 6.0 mm, Radial 
Dia 6.0 mm and 5 LineCross 9.0 mm tomograms. The following 
were included in the analysis: sex, age, first reported symptom, 
best corrected visual acuity, ophthalmic, family and general hi-
story, as well as complications and treatment.
One patient with subretinal neovascular membranes secon-
dary to choroid osteoma was treated with a total of 3 intravitre-
al anti-VEGF injections (bevacizumab 1.25 mg in 0.05 ml), ano-
ther patient with subretinal neovascular membranes secondary 
to choroid osteoma was treated with a total of 6 intravitreal 
anti-VEGF injections (ranibizumab 0.5 mg in 0.05 ml). Photody-
namic therapy (PDT) (Verteporfin 6 mg/m2; Visudyne, Bausch 
& Lomb, the laser energy 50J/cm2, irradiance of 600 mW/cm2) 
was used in one case.
Results
Observation of patients with choroidal osteoma continued 
for 11 years between 2005 and 2016. 3 men and 8 women 
were enrolled. The mean age on diagnosis was 30.5 years 
(29.6 years in women and 33 years in men). The right eye was 
involved in 4 patients and left eye in 6 patients. There was one 
case of bilateral choroidal osteoma. The most common first 
reported symptom was vision deterioration without metamor-
phopsia in 6 patients, vision deterioration with metamorphop-
sia in 3 patients, stand-alone metamorphopsia in 1 patient 
and in light flashes in 1 patient. The VA upon diagnosis was 
20/20 in 5 cases and 20/25 in 3 cases. There were also single 
cases of 20/50, 20/100, counting fingers at 3 meters and co-
unting fingers at 1 metre vision. Overall, 66% of studied eyes 
had VA equal to 20/25 or better and 33% of studied eyes had 
VA below 20/25. Ocular history was unremarkable in 9 patients 
(81.8%). General medical history was unremarkable in 8 pa-
tients (72.7%). Five patients (41.6%) presented with CNV, one 
with intraretinal fluid (IRF) without features of CNV, and another 
one with epiretinal membrane (ERM). All patients with CNV, 
were found to have RPE and Bruch membrane dystrophy, sub-
retinal fluid (SRF) and intraretinal haemorrhage (IRH). Additio-
nally, there was one case of subretinal haemorrhage (SRH).
At the end of the follow-up, the visual acuity was 20/20 
in 5 eyes and 20/25 in 2 eyes. There were also single cases 
of 20/40, 20/100, counting fingers in front of the eye and coun-
ting fingers at 1 metre vision, plus one patient was lost to fol-
low-up. 86% of patients without CNV had VA of 20/25 or better. 
In one female without CNV, the VA was counting fingers in front 
of the eye, which could have been attributable to amblyopia 
secondary to strabismus as well as subretinal fluid seconda-
ry to RPE atrophy. 80% of patients with CNV had VA of 20/40 
or lower.
Both PDT and anti-VEGF treatments improved CNV and sub-
retinal fluid. In a patient treated with PDT, VA did not impro-
ve yet it remained stable over the 18 month-long follow up. 
Anti-VEGF treatment improved VA by 3 rows and stabilised 
it for 20 months. Both treatments accelerated decalcification 
with RPE atrophy and subretinal fibrosis slowing down tumour 
growth (Tab. I).
Discussion
Choroidal osteoma is a tumour composed of cancellous bone 
and contains metabolically active bone cells responsible for con-
tinuous remodelling of tumour tissue (Fig. 1). Decalcification 
is a clinically important prognostic factor (10). Decalcification and 
tumour decomposition, first described by Trimbl in 1988, are pre-
sent in about 50% of cases and are characterized by RPE thinning 
and choriocapillaris atrophy. Tumour decalcification in the ma-
cular region is associated with low visual acuity (4, 7, 11, 12). 
Its onset can be spontaneous or induced by laser photocoagu-
lation or PDT, which stimulate osteoclast activity in the lesion 
(11, 13, 14, 15). Navajas et al. identified 2 different reflective pat-
terns in decalcified regions, the first consisting of areas of relati-
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ve hyperreflectivity with a lamellar appearance and the second 
being characterized by heterogeneously, hyperreflective, mound-
-like irregular areas. They suggested that the areas of lamellar 
reflective pattern would correspond to posterior scleral tissue 
where little or no tumour tissue is left, whereas hyperreflective 
mound-like irregular areas associated with some posterior sha-
dowing may correspond to tumour regions in which spongy orga-
nization was lost secondary to partial decalcification. (16). In our 
patients, we observed changes in tumour colour in funduscopy, 
alongside RPE and Bruch membrane atrophy in OCT, as well as 
characteristic changes in AF, which collectively indicate tumour 
decalcification (Fig. 2a, 2b).
Choroidal osteoma is asymptomatic in 8 to 30% of the ca-
ses (7, 8). Most commonly reported symptoms include blurred 
vision and metamorphopsia, just as it was the case in our pa-
tients. The tumour grows at a mean rate of 0.37 mm per year (7).
Sex/ 
Płeć
Age/ 
Wiek
Involved  
eye/  
Zajęte  
oko
First  
symptom/ 
 Pierwsze  
objawy
Ocular  
history/  
Wywiad  
okulistyczny
General  
history/  
Wywiad  
ogólny
Family  
history/  
Wywiad  
rodzinny
CNV
Comorbidi-
tie/  Zmiany 
współ-
istniejące
VA on 
diagnosis/ 
Ostrość 
wzroku 
podcas 
rozpoznania
Final VA/ 
Ostateczna 
ostrość 
wzroku
Treatment/ 
Zasto-
sowane 
leczenie
1 M 63 L decreased vision negative negative negative - - 20/20 20/20 O
2 F 17 R decreased vision
strabismus 
(RE) negative negative - IRF
count 
fingers at 
1 m
count 
fingers  
at 1 m
O
3 F 24 L decreased vision negative negative negative - ERM 20/20 20/20 O
4 M 15 R metamor-phopsia myopia negative negative - - 20/25 20/25 O
5 F 20 L decreased vision negative negative negative + IRH
count 
fingers at 
3 m
unknown anti-VEGF 
6 F 29 L decreased vision negative negative negative +
SRF
SRH 20/50 20/100 PDT
7 F 50 R
decreased 
vision
metamor-
phopsia
negative
hyperlipidemia
hypertension
Lyme disease
Aunt  
– brest 
cancer
- - 20/25 20/25 O
8 F 57 L decreased vision negative negative negative - - 20/20 20/20 O
9 M 21 R flashes negative negative negative + SRF 20/20 20/20 O
10 F 20 R, L
decreased 
vision
metamor-
phopsia
negative negative negative + in RE- in LE
IRH
SRF
SRH
20/25
20/20
count 
fingers  
in front  
of the eye
20/20
O
11 F 20 L
decreased 
vision
metamor-
phopsia
negative CMV negative + SRF 20/100 20/40 anti- VEGF
R – right, L - left, (+) – present, (-) – absent, RE – right eye, LE – left eye, M – male, F – female, IRF – Intraretinal fluid, SRF – subretinal fluid, CNV – choroidal neovascularization, ERM – epiretinal membrane, IRH – intraretinal 
hemorrhage, PDT – photodynamic therapy, Anti-VEGF therapy – anti-vascular endothelial growth factor therapy, BCVA – best corrected visual acuity, O – observation, CMV – cytomegalovirus
Tab. I. Clinical characteristics of patients with choroidal osteoma: BCVA, complications, comorbidities, and treatments.
Tab. I. Charakterystyka kliniczna pacjentów z kostniakiem naczyniówki: BCVA, powikłania, schorzenia współistniejące i zastosowane leczenie.
Fig. 1. Typical choroidal osteoma in fundus examination.
Ryc. 1. Typowy obraz kostniaka naczyniówki w badaniu dna oka.
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Current theories on the origin of choroidal osteoma include 
congenital causes (17), choristoma (5), inflammation (18, 19), 
and hormonal abnormalities (3, 20). Several cases of familial 
occurrence were reported (3, 17, 21, 22). There was no familial 
occurrence in our patients, though. Sporadic reports tie choroidal 
osteoma with Stargardt macular dystrophy (23), polypoid choroidal 
maculopathy (24), pregnancy (20, 25), orbital pseudotumour (18), 
intraocular inflammation (19) and histiocytosis X (26). No con-
nection was found between choroidal osteoma and biochemical 
abnormalities in blood, such as calcium, phosphorus, alkaline pho-
sphatase or urea nitrogen levels (3, 27). In line with this finding, 
the calcium-phosphate balance was within normal limits in our pa-
tients. One female in our sample was treated for hyperlipidaemia. 
Another female was treated for hypertension and had a history of 
Lyme disease. A third female had a history of CMV infection.
A standard diagnostic assessment of choroidal osteoma 
includes indirect imaging using Volk lens and ocular ultra-
sound (Fig. 3). OCT can aid both the diagnosis and assessing 
potential complications. Specifically, it enables evaluating 
the presence of subretinal fluid, retinal thickness, morphology 
and the structure of individual retinal layers. The greatest atten-
tion should be paid to the presence of neovascular membranes, 
continuity of ELM layers, photoreceptors and RPE. OCT can in-
dicate areas of variable reflectance, depending on the degree of 
tumour calcification. Decalcified areas are more hyperreflecti-
ve (28). Recently introduced swept-source OCT (SS-OCT) ena-
bles a more accurate visualisation picture of the choroid and of 
pathology, including tumour type differentiation (29, 30) (Fig. 4).
AF is helpful in detecting RPE atrophy, CNV and the charac-
teristic “spider vessels”. Autofluorescence increases in meta-
bolically active tissues and is, therefore, absent in RPE atrophy 
and dysfunction. Fluorescence of calcified areas is well prese-
rved and reduced in decalcified regions. It is very well visible 
in FA in our patients (Fig. 2). In indocyanine green angiogra-
phy (ICGA), hypofluorescence in early-stage ICGA and retention 
of dye in late-phase ICGA were observed. Both calcified and de-
calcified appeared hypofluorescent. ICGA enables imaging small 
blood vessels on tumour surface, especially in early-phase stu-
dy, whereas vascular networks which may leak are often not 
detected using FA (31).
Many authors draw attention to the problem of subretinal 
fluid accumulation in eyes with choroidal osteoma. Shields 
postulated that disruptions in RPE promote the growth of new 
choroidal vessels (27). Alternatively, Foster’s theory assumes 
that CNV is the extension of the osteoma vessels (32). This hy-
pothesis is supported by osteoclast detection in surgically re-
moved neovascular membranes (33). In fact, CNV was only 
found in 23% of eyes with subretinal fluid. High metabolic rate 
in choroidal osteoma, can restrict blood flow in adjacent tis-
sues, particularly in RPE overlying tissue, which may increase 
VEGF expression. Presumably, then, CNV develops secondarily 
to the disruption of the epithelium – Bruch complex (33) (Fig. 5).
VA reduction can be caused by progressive retinal atro-
phy, subretinal fluid accumulation, and subretinal haemorr-
hage with or without the presence of CNV (4). The subretinal 
Fig. 2. Colour change within the tumour indicating its decalcification.
Ryc. 2. Zmiana zabarwienia guza wskazująca na jego dekalcyfikację.
a.
b.
Fig. 3. Ultrasound image of choroidal osteoma.
Ryc. 3. Obraz kostniaka naczyniówki w badaniu ultrasonograficznym.
Fig. 4. The choroidal osteoma disrupting Bruch membrane and cau-
sing retinal elevation seen in an OCT.
Ryc. 4. Kostniak naczyniówki w badaniu OCT – widoczne zaburzenie 
przebiegu błony Brucha i uniesienie siatkówki.
131Klinika Oczna 2018, 120 (3)ISSN 0023-2157 Index 362646
AnnA MArkiewicz, JustynA JędrychowskA-JAMborskA, bożenA roMAnowskA-dixon
haemorrhage can be caused by intracranial pressure elevated 
as a result of Valsalva manoeuvre (34). This very mechanism 
was observed in one female in our sample. In their report, Koylu 
et al. present a case of spontaneously resolving subretinal ha-
emorrhage secondary to choroidal osteoma unrelated to CNV. 
They believe that bleeding may have been caused by spontane-
ous rupture of choroidal vessels which were distorted by the le-
sion and suggest that clinicians should rule out the presence 
of CNV in secondary subretinal haemorrhage of choroidal oste-
oma and prevent unnecessary treatment attempts in the first 
step as spontaneous recovery is the easiest and safest 
way (35). Another study provides CNV prevalence rates as 31% 
in 5 years, 31–47% in 10 years, and 56% in 20 years (36). In our 
sample, CNV was present in 41.6% of eyes within 10 years.
As far as treatment is concerned, some authors state that la-
ser photocoagulation in the treatment of choroidal osteoma has 
limited efficacy due to the lack of pigment in the tumour and to 
the atrophy of retinal pigment epithelium (37). This method was 
not used in any of our patients. PDT, administered at the stan-
dard dose of 6 mg/m2, offers stable visual acuity, reduced meta-
morphopsia and CNV improvement. In one female from our sam-
ple, the best corrected visual acuity (BCVA) remained stable for 
18 months after PDT and was accompanied by CNV and subreti-
nal fluid resolution. Shields et al. also described a case of a sub-
foveal CNV accompanying choroidal osteoma, successfully tre-
ated using PDT (13). The results of another study show that PDT 
was effective in only 25% of classic subfoveal CNV complicating 
choroidal osteoma (8). PDT in choroidal osteoma increases the 
risk of tumour decalcification. Our study revealed accelerated 
tumour decalcification with subretinal fibrosis after PDT, which 
whilst limiting further tumour growth, additionally accelerated 
RPE atrophy in the macula. Shields et al. state that PDT may be 
a therapeutic option for CNV and for induction of decalcification 
for perimacular tumours to prevent their growth towards the 
macula (13). Our observations seem to confirm it. In some cen-
tres, PDT is combined with intravitreal injections of anti-VEGF 
to treat CNV complicating choroid osteoma. The first treatment 
of this kind, combining PDT with ranibizumab was described 
by Morris et al. and resulted in visual acuity improvement from 
20/80 to 20/20 (38).
The results of recent studies suggest that intravitreal anti-
-VEGF injections offer a good option to improve visual acuity 
(30, 33). In Poland, approved anti-VEGF products include be-
vacizumab, ranibizumab and aflibercept, with bevacizumab 
used off-label. All anti-VEGF agents are angiogenesis inhibitors, 
which block or slow down growth of pathological blood ves-
sels in the subretinal space and/or under the RPE. Using rani-
bizumab instead of bevacizumab reduces systemic exposure 
as it has a much shorter half-life in serum. Good response to 
anti-VEGF therapy can also be explained by young age of pa-
tients with choroidal osteoma. One female in our sample rece-
ived 6 intra vitreal anti-VEGF injections of ranibizumab, achieving 
partial resolution of CNV and subretinal fluid, as well as BCVA 
improvement from 0.2 to 0.5 with its subsequent stabilisation 
for 20 months.
Summary
The literature review and our long–term observations in-
dicate that choroidal osteoma is an extremely rare tumour af-
fecting mostly young women and located within the posterior 
pole. Diagnosis should include ultrasound examination, which 
shows hyperechoic tumour. Over time, the tumour gradually 
decalcifies, which is clearly visible in fluorescein angiography 
and OCT. Possible complications can include subretinal mem-
brane. Choroidal osteomas can remain asymptomatic. Intravi-
treal injections of anti-VEGF agents or, optionally, combined tre-
atment with PDT, should be considered as adjunctive treatment 
of choroidal osteoma.
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